Malaria is one of the most frequently occurring infectious diseases worldwide, with almost 1
million deaths and an estimated 243 million clinical cases annually. Several candidate …

Macaques have served as models for more than 70 human infectious diseases of diverse
etiologies, including a multitude of agents—bacteria, viruses, fungi, parasites, prions. The …

The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based
particle vaccine, RTS, S, which targets the pre-erythrocytic stage of Plasmodium falciparum …

CD4+ T cells have a crucial role in mediating protection against a variety of pathogens
through production of specific cytokines. However, substantial heterogeneity in CD4+ T-cell …

Background To further increase the efficacy of malaria vaccine RTS, S/AS02A, we tested the
RTS, S antigen formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals) …

Background Blood-stage malaria vaccines are intended to prevent clinical disease. The
malaria vaccine FMP2. 1/AS02A, a recombinant protein based on apical membrane antigen …

Abstract We describe the MalariaGEN Pf7 data resource, the seventh release of
Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises …

Objective The antigen, falciparum malaria protein 1 (FMP1), represents the 42-kDa C-
terminal fragment of merozoite surface protein-1 (MSP-1) of the 3D7 clone of P. falciparum …

Vaccination with the pre-erythrocytic malaria vaccine RTS, S induces high levels of
antibodies and CD4+ T cells specific for the circumsporozoite protein (CSP). Using a …

Background This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an
experimental malaria vaccine comprised of the recombinant Plasmodium falciparum protein …